Simple Summary Melanoma is an aggressive form of skin cancer and the leading cause of
skin cancer-related deaths. Current therapies, including those targeting oncogenic pathways …

The incidence of melanoma is increasing faster than that of any other cancer, and predicted
to double every 10-20 years. Surgery can be curative in Stage I, II, or III disease, but 75% of …

Despite major advances in the treatment of metastatic melanoma, treatment failure is still
inevitable in most cases. Manipulation of key epigenetic regulators, including inhibition of …

Bromodomain and extraterminal domain inhibitors (BETi) represent promising therapeutic
agents for metastatic melanoma, yet their mechanism of action remains unclear. Here we …

Metastatic melanoma remains a mostly incurable disease. Although newly approved
targeted therapies are efficacious in a subset of patients, resistance and relapse rapidly …

Genomic diversity among melanoma tumors limits durable control with conventional and
targeted therapies. Nevertheless, pathologic activation of the ERK1/2 pathway is a linchpin …

We defined the lethal interaction between the novel therapeutic GZ17-6.02 and the standard
of care combination of the MEK1/2 inhibitor trametinib and the B-RAF inhibitor dabrafenib in …

Despite novel therapies for melanoma, drug resistance remains a significant hurdle to
achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic …

Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising
therapeutic effect on melanoma. The development of strategies to better kill melanoma cells …

Simple Summary Melanoma affects over 300,000 people worldwide every year. Recent
advancements in therapeutic treatments for melanoma patients, such as targeted therapies …